Ondansetron 4 Odf Pharma-Q, Ondansetron 8 Odf Pharma-Q 4 mg, 8 mg Orodispersible films
PDF Leaflet Revision Date: 05 February 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Management of nausea and vomiting induced by chemotherapy, radiotherapy, and post-operative nausea and vomiting.
Dosage (summary)
Adults: 8 mg orally 1-2 hours before treatment, then 8 mg every 12 hours. Max 8 mg/day in hepatic impairment.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in first 12 weeks of pregnancy; avoid breastfeeding.
Key Drug Interactions
- Apomorphine
- QT prolonging medications
- Serotonergic medicines
Contraindications
- Hypersensitivity to ondansetron
- Congenital long QT syndrome
- First 12 weeks of pregnancy
Common side effects
- Headache
- Constipation
- Dysrhythmias
Counselling Points
- Do not drive or operate machinery until effects are known.
- Monitor for signs of hypersensitivity.
- Avoid use with other QT prolonging drugs.
Serious warnings
- QT prolongation
- Myocardial ischemia
- Serotonin syndrome
Important Disclaimer
The Ondansetron 4 Odf Pharma-Q, Ondansetron 8 Odf Pharma-Q 4 mg, 8 mg Orodispersible films professional information leaflet below is the property of Pharma-Q Holdings and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
